TC Biopharm (Holdings) PLC e phatlalalitse hore e amohetse MHRA le tumello ea Komiti ea Boitšoaro ea Lipatlisiso ho qala liteko tsa kliniki tsa kalafo ea lisele tsa gamma-delta tsa OmnImmune® bakeng sa kalafo ea Acute Myeloid Leukemia (AML).
OmnImmune® an allogeneic unmodified cell therapy e nang le lisele tse kentsoeng le tse atolositsoeng tsa gamma delta T e se e fumane lebitso la setlhare sa likhutsana bakeng sa kalafo ea bakuli ba tšoeroeng ke mofetše oa mali le moko oa masapo. Liteko tsa Phase 2/3 li tla qala ho ingolisa halofong ea pele ea 2022 UK ka katoloso ho kena US kamora nakoana kamora moo.
"Re thabile haholo ho fumana tumello ea MHRA le ea Melao ea Boitšoaro ea Lipatlisiso, e tšoaeang mohato oa ho qetela oa ho fana ka protocol le ho qala ka ts'ebetso ea liteko tsa bongaka tsa kalafo ea rona ea AML," ho boletse Bryan Kobel, CEO oa TC BioPharm. "Ka mor'a ho phatlalatsa Phatlalatso ea Lithethefatsi tsa Likhutsana ho tsoa ho FDA, joale re bonts'itse bokhoni ba rona ba ho tsamaisa lits'ebetso tse tšoanang bakeng sa liteko tsa tleliniki Amerika le UK/EU. Liphetho tse ntle tse bontšitsoeng ke OmnImmune® litekong tsa bongaka tsa Phase 1b/2a lia khothatsa ebile li tiisa tumelo ea rona ea bokhoni ba eona ba ho ba kalafo e sebetsang bakeng sa Acute Myeloid Leukemia.
SEO U LOKELANG HO SE NKA HO SEHLOOHO ENA:
- OmnImmune® an allogeneic unmodified cell therapy e nang le li-cell T tsa gamma Delta T tse se li fumane lebitso la setlhare sa likhutsana bakeng sa ho alafa bakuli ba tšoeroeng ke mofetše oa mali le moko oa masapo.
- Liphetho tse ntle tse bontšitsoeng ke OmnImmune® litekong tsa bongaka tsa Mokhahlelo oa 1b/2a lia khothatsa ebile li tiisa tumelo ea rona bokhoning ba eona ba ho ba kalafo e sebetsang bakeng sa Acute Myeloid Leukemia.
- TC Biopharm (Holdings) PLC e phatlalalitse hore e amohetse MHRA le tumello ea Komiti ea Boitšoaro ea Lipatlisiso ho qala liteko tsa kliniki tsa kalafo ea lisele tsa gamma-delta tsa OmnImmune® bakeng sa kalafo ea Acute Myeloid Leukemia (AML).
